TrialsgrambetaRCTs are beautiful

ODYSSEY OUTCOMES

2018

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

In 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).

Result

Efficacy: Composite of CHD death, nonfatal MI, ischaemic stroke, or unstable angina requiring hospitalisationHR 0.85 (95% CI 0.78-0.93) · P < 0.001

Below 1 favours alirocumab, above 1 favours placebo.

Event rates
Absolute difference
1.6 points
NNT
63

Absolute difference and NNT are derived from the event rates.

Also reported: All-cause death lower (3.5% vs 4.1%; HR 0.85, 95% CI 0.73-0.98), greatest benefit with baseline LDL-C ≥100 mg/dL.

Original publication
Subtopic
PCSK9 inhibitor
Design
Double-blind, placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Schwartz GG, et al. N Engl J Med. 2018;379(22):2097-2107.doi 10.1056/NEJMoa1801174

Discussion & critique

Benefit concentrated in patients with higher baseline LDL-C, and absolute risk reduction was modest. Informs guidelines to reserve PCSK9 inhibitors for very-high-risk post-ACS patients not at LDL goal on maximally tolerated statin/ezetimibe.

Discussed in podcasts